This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Shares of Northfield Laboratories (NFLD) were among the best-performing health-related stocks Tuesday, climbing 10% after an independent data monitoring committee recommended that the company's Phase III trial of PolyHeme continue without modification.

"This is the first time a hemoglobin-based oxygen-carrying resuscitative fluid has successfully passed this patient evaluation milestone in the high-risk trauma population," the company said. Northfield is conducting the Phase III trial to evaluate the safety and efficacy of PolyHeme, which is a human hemoglobin-based oxygen-carrying resuscitative fluid that's administered to patients in hemorrhagic shock following a traumatic injury. The company plans to complete enrollment early next year. Shares were trading up $1.29 to $13.74.

Pro-Dex (PDEX) plunged 22% after the maker of technology-based products used by the medical, dental and scientific research markets posted lower year-over-year earnings and cut its profit outlook. The company reported fiscal first-quarter earnings of $262,000, or 3 cents a share, on sales of $3.8 million. A year earlier, the company posted earnings of $462,000, or 5 cents share, on sales of $3.3 million. Pro-Dex attributed the earnings decline to an unfavorable shift in product mix and increased operating expenses.

The company now sees fiscal 2006 earnings of 21 cents to 26 cents a share, down from its previous view of 26 cents to 30 cents a share. Pro-Dex continues to expect sales of $16 million to $18 million for the fiscal year ending next June. Shares were trading down 73 cents to $2.52.

Guidant (GDT) shares rose 9% after Johnson & Johnson (JNJ) agreed to acquire the company for about $21.5 billion, almost $4 billion less than its original offer. Johnson & Johnson had wavered on the acquisition after Guidant was hit with a series of product recalls.

The companies' new deal is valued at $63.08 a share, below Johnson & Johnson's original offer of $76 a share. Guidant shareholders will receive $33.25 a share in cash and 0.493 Johnson & Johnson shares. "The board believes that it is in the best interest of shareholders to proceed with the merger agreement at the revised terms," Guidant said. "Our enthusiasm for this merger and its potential continues. This agreement makes sense for Guidant shareholders and its employees." Shares of Guidant were trading up $4.92 to $62.67, while shares of Johnson & Johnson rose $2.83, or 5%, to $63.34.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASDAQ 4,449.5640 -22.5440 -0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs